Stocks · News reference
Recent Filing Shows That Rep. Maria Elvira Salazar Bought Over $34K Worth of Merck & Co Stock
September 9, 2026 records indicate that Representative Maria Elvira Salazar filed a purchase of Merck & Co (NYSE:MRK), valued between $34,006 and $160,000. According to the September filing, the transaction occurred
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Chubb (CB) Outpaces Stock Market Gains: What You Should Know
Chubb (CB) closed at $348.25, up 2.6%, outperforming the S&P 500's 1.06% gain. Analysts expect Q3 earnings of $6.22 per share (down 16.96% YoY) with revenue of $16.71 billion (up 3.59% YoY). The company holds a Zacks Rank #3 (Hold) with a Forward P/E of 12.41, trading at a premium to its industry average of 11.55.
Chubb (CB) Stock Falls Amid Market Uptick: What Investors Need to Know
Chubb (CB) closed at $338.31, down 1.59% from the previous day, underperforming the S&P 500's 0.72% gain. The stock has declined 5.01% over the past month. Upcoming earnings are expected to show an EPS of $6.35 (down 15.22% YoY) with revenue projected at $16.71 billion (up 3.59% YoY). Chubb holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 12.51, trading at a premium to its industry average.
Congresswoman Bets on Elon Musk, Warren Buffett: Here’s the Latest Stock Transactions
A congresswoman recently bought stocks connected to Warren Buffett and Elon Musk.
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff
GSK's Specialty Medicines segment, accounting for over 40% of sales, grew 14% in H1 2026 driven by HIV, respiratory, and oncology products. The company is accelerating R&D with over 20 phase III starts planned for 2026. However, GSK faces a significant challenge as dolutegravir patents expire in 2028-2029, threatening its HIV franchise which generated £2.74 billion in H1 2026. GSK is relying on long-acting HIV injectables and next-generation pipeline products to offset future generic competition.
HSBC Maintains Buy on Merck & Co, Raises Price Target to $172
HSBC analyst Rajesh Kumar maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $150 to $172.